Radiopharm Theranostics reported a 93% success rate in its Phase 2b trial of RAD 101 for brain metastases imaging and aims to start a Phase 3 trial in Q4 2026. The company also raised $12.5 million post-quarter to support ongoing development.
- RAD 101 Phase 2b trial hits 93% primary endpoint concordance
- Phase 3 registrational trial planned for Q4 2026
- RAD 204 Phase 1 shows durable partial response in advanced cancers
- Quarter-end cash fell to $4.1 million with $15 million quarterly burn
- Post-quarter $12.5 million institutional raise and $6 million SPP launched
RAD 101 Phase 2b Trial Surpasses Expectations
Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX) has reported positive results from its Phase 2b clinical trial of RAD 101, an imaging agent targeting fatty acid synthase in patients with recurrent brain metastases. Impressively, 93% of evaluable patients achieved the primary endpoint, showing concordance with MRI imaging. An interim analysis further revealed an 86% sensitivity rate in biopsy-confirmed cases, underscoring the agent’s diagnostic potential.
RAD 101’s significance is amplified by its FDA Fast Track Designation, aimed at expediting approval to benefit the over 300,000 U.S. patients annually diagnosed with cerebral metastases. The company plans to initiate a Phase 3 registrational trial in the U.S. and internationally in Q4 2026, partnering with Siemens Healthineers to manufacture and distribute the imaging doses.
Encouraging Therapeutic Pipeline Progress
Beyond RAD 101, Radiopharm continues to advance multiple Phase 1 trials for therapeutic candidates. RAD 204, a nanobody targeting PD-L1, showed early clinical promise with a durable RECIST-confirmed partial response in the first patient dosed at the 90mCi level, maintaining tumor shrinkage of up to 43% and progression-free status after more than seven months.
Similarly, RAD 202, targeting HER2-positive tumors, demonstrated meaningful tumor uptake and a clean safety profile in its Phase 1 HEAT trial. The Data Safety and Monitoring Committee has greenlit dose escalation, with enrolment for the next cohort expected to complete by mid-2027.
Other candidates such as RV 01, RAD 402, and RAD 301 are progressing through early-stage trials, exploring novel targets across a spectrum of solid tumors including prostate and pancreatic cancers.
Financial Position and Capital Raising Activity
Radiopharm ended the June quarter with $4.1 million in cash, down sharply from $19.2 million at the prior quarter’s end. The company recorded net operating cash outflows of approximately $15 million, driven largely by accelerated clinical development and staff costs aligned with key milestones such as the RAD 101 Phase 2b success and RAD 204 partial response.
Post-quarter, the company bolstered its cash position by raising $12.5 million through an institutional offer and launching a $6 million Share Purchase Plan, which has already attracted subscriptions up to $3 million. Additionally, Radiopharm received a $5.9 million Australian R&D tax incentive refund, providing further liquidity.
Management expects the elevated cash burn to moderate in upcoming quarters as milestone-driven expenditures ease and ongoing capital management strategies take effect.
Strategic Positioning in Radiopharmaceuticals
CEO Riccardo Canevari emphasised the company’s momentum across its diverse pipeline of diagnostic and therapeutic radiopharmaceuticals. With six active clinical programs spanning small molecules, nanobodies, and monoclonal antibodies, Radiopharm aims to carve out a leading position in precision oncology treatments.
The company’s multi-pronged approach targets some of the most challenging cancers, including brain metastases, lung, breast, and pancreatic cancers. The combination of positive clinical data, regulatory fast-tracking, and strategic manufacturing partnerships positions Radiopharm to potentially deliver innovative new medicines to patients while creating shareholder value.
Bottom Line?
Radiopharm’s clinical advances and capital raise set the stage for a pivotal Phase 3 trial, but sustaining funding and translating early trial success into commercial outcomes remain critical hurdles.
Questions in the middle?
- Will the Phase 3 trial of RAD 101 replicate the high concordance rates seen in Phase 2b?
- How will Radiopharm manage cash flow as clinical programs scale and operating costs evolve?
- What timelines and data readouts can investors expect from the therapeutic candidates RAD 204 and RAD 202?